Googles Shweta Maniar writes about what shes learned traveling to conferences across the planet to talk about the convergence ...

Non-hallucinogenic neuroplastogens offer benefits over classical psychedelics, including simpler delivery, stronger IP ...

As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

Leading a biotech company in this dynamic industry requires a strong, agile team and a championship mindset. Applying the same strategies that led my Philadelphia Eagles to the Superbowl, just as a ...

Crystalline forms of compounds and salts are frequently claimed in chemical patents, including in pharmaceuticals and agrochemicals. Different crystalline forms of the same substance — that is, ...

Amber Salzman, Ph.D., CEO at Epicrispr Biotechnologies, joined the Business of Biotech live in Boston to talk about epigenetic editing, working with the FDA, using AI for clinical endpoints, and more.

What are the key life sciences trends to watch during the second half of 2025? Evolving regulations, precision medicine, and private equity investment in oncology, according to experts at KPMG.

A key focus of Part III in this clinical trial payment series is the tax implications of trial payments. This article emphasizes that while reimbursements for out-of-pocket expenses are tax-exempt and ...

In the pharmaceutical industry, regulatory affairs (RA) and pharmacovigilance (PV) are often viewed as separate entities with distinct responsibilities. RA navigates the complex landscape of drug ...

In the competitive landscape of the global pharmaceutical industry, collaboration and consolidation often pave the way for success—especially for smaller companies aiming to make a significant impact.

<p>Biopharma entrepreneur Damon Race found breakthrough gene and gene-editing therapies close to home, licensing innovations from UNC-Chapel Hill and Duke University to launch his latest venture.</p> ...